Loading...
XLON
PXS
Market cap24mUSD
Jul 16, Last price  
0.78GBP
1D
0.00%
1Q
40.91%
Jan 2017
-8.82%
IPO
-87.55%
Name

Provexis PLC

Chart & Performance

D1W1MN
P/E
P/S
2,267.02
EPS
Div Yield, %
Shrs. gr., 5y
2.79%
Rev. gr., 5y
20.01%
Revenues
802k
+105.68%
310,000268,00067,000162,0005,00015,00050,0003,478,0005,559,5913,96738,22491,649227,618235,804322,189347,937505,329426,168389,916801,964
Net income
-586k
L+52.18%
-1,092,000-49,000-2,438,000-1,189,000-4,571,000-1,648,000-1,984,000-3,873,000-4,338,600488,353-435,598-409,569-380,087-448,108-513,032-406,229-341,007-224,250-385,241-586,243
CFO
-191k
L-63.16%
-1,265,000-2,749,000-2,179,000-1,487,000-1,350,000-1,500,000-2,053,000-2,166,000-1,433,348-573,344-404,776-366,099-430,302-363,052-384,014-334,641-262,075-213,537-519,852-191,498
Earnings
Sep 29, 2025

Profile

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.
IPO date
Jun 24, 2005
Employees
2
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
802
105.68%
390
-8.51%
Cost of revenue
1,285
811
Unusual Expense (Income)
NOPBT
(483)
(421)
NOPBT Margin
Operating Taxes
(14)
(33)
Tax Rate
NOPAT
(469)
(388)
Net income
(586)
52.18%
(385)
71.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
35
BB yield
-0.20%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(189)
(379)
Cash flow
Cash from operating activities
(191)
(520)
CAPEX
Cash from investing activities
2
887
Cash from financing activities
35
FCF
(68)
(523)
Balance
Cash
189
379
Long term investments
Excess cash
149
360
Stockholders' equity
(18,513)
(11,446)
Invested Capital
18,703
12,093
ROIC
ROCE
EV
Common stock shares outstanding
2,217,822
2,216,805
Price
0.01
-20.89%
0.01
-7.06%
Market cap
13,861
-20.85%
17,513
-6.81%
EV
13,138
16,602
EBITDA
(483)
(421)
EV/EBITDA
Interest
Interest/NOPBT